News
KIST/Angelini Pharma/Cureverse Sign Agreement for Development of Brain Disease Therapeutic Technologies (Nov. 12, 2024)
- Date : 2024-12-17
- Views : 64
-
Writer
International Cooperation Team
-
Att.
KIST Signs Collaboration Agreement with Angelini Pharma and Cureverse for Development of Therapeutic Technologies for Brain Diseases
On November 12, 2024, the Korea Institute of Science and Technology (KIST), led by President Sang Rok Oh, announced the signing of a strategic collaboration agreement with the Italian global pharmaceutical company Angelini Pharma and Cureverse, a research institute spin-off backed by KIST, focused on advancing the development of innovative therapeutics for brain diseases. Under this partnership, KIST will support technology licensing agreements between Cureverse and Angelini Pharma, provide research resources and infrastructure aimed at developing new therapeutics related to brain health, and work to strengthen each institution’s efforts to commercialize their technologies.
Notably, Cureverse recently entered into a USD 370 million (approx. KRW 506 billion) technology transfer agreement with Angelini Pharma on October 16 for its oral dementia drug candidate, CV-01.
The signing ceremony, held at KIST's headquarters in Seoul, was attended by KIST President Sang Rok Oh, Angelini Pharma’s Chief Scientific Officer (CSO) Rafal Kaminski, Cureverse CEO Seong-Jin Cho, and Hee-Kwon Jeong, Chairman of the Innopolis Foundation.
Regarding the signing, KIST President Sang Rok Oh stated, “KIST is committed to solving pressing societal challenges through innovative research. We anticipate that this collaboration with Angelini Pharma and Cureverse will deliver significant advancements in brain disease therapeutics. Moving forward, we will continue expanding partnerships with domestic and international institutions and companies to foster ongoing technological innovation.”
Rafal Kaminski, CSO of Angelini Pharma, remarked, “This agreement will accelerate Angelini Pharma’s global drug development and commercialization initiatives. Our collaboration with KIST and Cureverse will serve as a critical stepping stone for advancing brain disease treatments.”
Cureverse CEO Seong-Jin Cho added, “As a bio-startup nurtured through KIST’s support, Cureverse is thrilled to seize the opportunity to enter the global market that this agreement presents. We are dedicated to continuing our work with KIST and Angelini Pharma to develop groundbreaking therapeutics for brain diseases.”
Chairman Hee-Kwon Jeong of the Innopolis Foundation commented, “Research institute spin-offs like Cureverse represent the core assets of research and development clusters. This agreement establishes an essential bridge for startups within these clusters to expand into the global market. Innopolis Foundation will remain steadfast in supporting innovative companies with achieving international success.”
Through this agreement, KIST aims to facilitate technology collaboration between Angelini Pharma and Cureverse, further paving the way for domestic bio-companies to enter the global market, and driving innovation in brain disease therapeutics research.
Cureverse, which has benefitted from KIST’s technology transfers, funding support, and infrastructure as part of the Hongneung Innopolis Cluster, has been advancing the development of innovative brain disease therapeutics. This partnership will solidify its foundation for achieving greater success in the global biotechnology market.